Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study
Mara Persano,Andrea Casadei-Gardini,Toshifumi Tada,Goki Suda,Shigeo Shimose,Masatoshi Kudo,Federico Rossari,Changhoon Yoo,Jaekyung Cheon,Fabian Finkelmeier,Ho Yeong Lim,José Presa,Gianluca Masi,Francesca Bergamo,Elisabeth Amadeo,Francesco Vitiello,Takashi Kumada,Naoya Sakamoto,Hideki Iwamoto,Tomoko Aoki,Hong Jae Chon,Vera Himmelsbach,Massimo Alberto Iavarone,Giuseppe Cabibbo,Margarida Montes,Francesco Giuseppe Foschi,Caterina Vivaldi,Caterina Soldà,Takuya Sho,Takashi Niizeki,Naoshi Nishida,Christoph Steup,Mariangela Bruccoleri,Masashi Hirooka,Kazuya Kariyama,Joji Tani,Masanori Atsukawa,Koichi Takaguchi,Ei Itobayashi,Kunihiko Tsuji,Toru Ishikawa,Kazuto Tajiri,Hironori Ochi,Satoshi Yasuda,Hidenori Toyoda,Chikara Ogawa,Takashi Nishimura,Takeshi Hatanaka,Satoru Kakizaki,Noritomo Shimada,Kazuhito Kawata,Atsushi Hiraoka,Fujimasa Tada,Hideko Ohama,Kazuhiro Nouso,Asahiro Morishita,Akemi Tsutsui,Takuya Nagano,Norio Itokawa,Tomomi Okubo,Michitaka Imai,Hisashi Kosaka,Atsushi Naganuma,Yohei Koizumi,Shinichiro Nakamura,Masaki Kaibori,Hiroko Iijima,Yoichi Hiasa,Luigi Mascia,Silvia Foti,Silvia Camera,Fabio Piscaglia,Mario Scartozzi,Stefano Cascinu,Margherita Rimini
DOI: https://doi.org/10.1159/000541018
2024-10-11
Oncology
Abstract:Introduction: The most frequently used first-line treatment in patients with advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab. Upon progression after this treatment, the standard of care in many countries is sorafenib, due to the lack of reimbursement for other drugs. Several randomized trials are currently underway to clarify the best second-line therapy in patients with HCC. This real-world study aimed to compare outcomes reached by lenvatinib and sorafenib second-line therapy in this setting. Methods: The overall cohort included 891 patients with HCC from 5 countries treated with atezolizumab plus bevacizumab in first-line setting between October 2018 and April 2022. At the data cut-off (May 2022), 41.5% of patients were continuing a first-line treatment, 5.5% were lost at follow-up, and 53.0% of patients had progressive disease after first-line therapy. 51.5% of patients with progressive disease received a second-line treatment, while 48.5% did not receive any subsequent therapy. Between patients receiving second-line treatment, 11.1% of patients underwent transarterial chemoembolization, 21.0% received sorafenib, 35.4% underwent lenvatinib, and 32.5% were treated with other drugs. Results: Lenvatinib second-line subgroup achieved a median overall survival (mOS) of 18.9 months, significative longer (p = 0.01; hazard ratio [HR]: 2.24) compared to sorafenib subgroup that reached a mOS of 14.3 months. The multivariate analysis highlighted albumin-bilirubin 1 grade (p < 0.01; HR: 5.23) and lenvatinib second-line therapy (p = 0.01; HR: 2.18) as positive prognostic factors for OS. The forest plot highlighted a positive trend in terms of OS in favor of patients treated with lenvatinib second-line regardless of baseline characteristics before first-line therapy. Conclusion: These results suggest that, in patients with HCC progressed to first-line atezolizumab plus bevacizumab, lenvatinib second-line therapy is associated to an improved survival compared to sorafenib.